ValuEngine downgraded shares of Neuronetics (NASDAQ:STIM) from a buy rating to a hold rating in a research report released on Tuesday, ValuEngine reports.

Shares of NASDAQ:STIM opened at $4.88 on Tuesday. Neuronetics has a 12-month low of $4.81 and a 12-month high of $25.97. The company has a current ratio of 6.10, a quick ratio of 5.95 and a debt-to-equity ratio of 0.51. The company has a market cap of $100.93 million, a PE ratio of -1.81 and a beta of 0.98. The stock has a 50 day moving average of $8.72 and a 200 day moving average of $11.36.

Neuronetics (NASDAQ:STIM) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Neuronetics had a negative return on equity of 42.24% and a negative net margin of 45.35%. The business had revenue of $16.00 million during the quarter, compared to the consensus estimate of $16.13 million. Equities research analysts predict that Neuronetics will post -1.61 earnings per share for the current fiscal year.

In other Neuronetics news, CEO Christopher Thatcher sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $10.74, for a total value of $214,800.00. Corporate insiders own 12.00% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in Neuronetics by 4.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,506 shares of the company’s stock worth $394,000 after purchasing an additional 1,270 shares during the period. Northern Trust Corp boosted its stake in Neuronetics by 4.6% in the 2nd quarter. Northern Trust Corp now owns 133,618 shares of the company’s stock worth $1,671,000 after purchasing an additional 5,877 shares during the period. Tower Research Capital LLC TRC bought a new position in Neuronetics in the 3rd quarter worth approximately $57,000. BlackRock Inc. boosted its stake in Neuronetics by 6.2% in the 2nd quarter. BlackRock Inc. now owns 978,044 shares of the company’s stock worth $12,235,000 after purchasing an additional 57,297 shares during the period. Finally, Novo Holdings A S boosted its stake in Neuronetics by 11.0% in the 2nd quarter. Novo Holdings A S now owns 582,798 shares of the company’s stock worth $7,291,000 after purchasing an additional 57,798 shares during the period. Institutional investors and hedge funds own 79.97% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Further Reading: What is a back-end load?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.